Valuation: CorMedix Inc.

Market Cap 596M 523M 487M 448M 840M 56.96B 855M 5.78B 2.26B 28.25B 2.24B 2.19B 97.6B P/E 2026 *
15.1x
P/E 2027 * 86.4x
Enterprise Value 596M 523M 487M 448M 840M 56.96B 855M 5.78B 2.26B 28.25B 2.24B 2.19B 97.6B EV / Sales 2026 *
1.78x
EV / Sales 2027 * 2.09x
Free-Float
92.47%
Yield 2026 *
-
Yield 2027 * -
1 day-3.42%
1 week-10.44%
Current month-6.56%
1 month-3.99%
3 months-3.10%
6 months-5.35%
Current year-36.93%
1 week 7.28
Extreme 7.28
8.2
1 month 7.28
Extreme 7.28
8.98
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
14.96
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 09/05/2022
Director of Finance/CFO 54 28/08/2025
Compliance Officer 66 11/12/2023
Director TitleAgeSince
Director/Board Member 67 05/08/2015
Chairman 81 02/08/2017
Director/Board Member 70 15/08/2011
Date Insider Type Main position Quantity % Market Cap.
04/02/26 Free

Chief Operating Officer

36,006 0.0457%
04/02/26 Free

Chief Executive Officer

77,156 0.0979%
04/02/26 Free

General Counsel

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
-3.42%-10.44%-38.77%+64.46% 596M
+1.02%+4.35%+56.73%+23.90% 323B
+1.76%+7.45%+27.60%-10.04% 70.11B
+2.66%+6.53%+45.05%+91.79% 9.66B
-0.19%+0.06%+3.49%-2.33% 8.51B
-2.93%+3.52%-22.51%-5.36% 4.37B
-3.73%+0.26%-5.97%+10.94% 3.75B
-1.81%+2.17%-42.24%+8.06% 3.66B
+0.40%-1.67%+40.89%+54.73% 2.73B
-0.87%-3.48%-5.55%-9.14% 2.11B
Average -0.73%+0.41%+5.87%+22.70% 42.84B
Weighted average by Cap. +1.01%+3.04%+47.90%+18.90%

Financials

2026 *2027 *
Net sales 335M 294M 273M 251M 471M 31.96B 480M 3.24B 1.27B 15.85B 1.26B 1.23B 54.77B 285M 250M 233M 214M 402M 27.25B 409M 2.77B 1.08B 13.51B 1.07B 1.05B 46.69B
Net income 47.14M 41.37M 38.53M 35.44M 66.43M 4.5B 67.56M 457M 179M 2.23B 177M 173M 7.72B 8.61M 7.56M 7.04M 6.47M 12.13M 823M 12.34M 83.48M 32.67M 408M 32.32M 31.63M 1.41B
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
28/07/26 US$7.335 -3.49% 701,958
27/07/26 US$7.600 -3.43% 1,183,744
24/07/26 US$7.870 -2.24% 625,290
23/07/26 US$8.050 +1.39% 698,511
22/07/26 US$7.940 -3.05% 860,115
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.600USD
Average target price
15.00USD
Spread / Average Target
+97.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock